By Mungukende Joshua.
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro for reducing the risk of serious cardiovascular events in certain adults with type 2 diabetes and cardiovascular disease.
The August 28 decision expands the use of the drug beyond its existing diabetes treatment role.
The development is significant for the global healthcare industry as pharmaceutical companies continue to develop treatments that address both diabetes and related health complications.
For patients, however, medical experts continue to stress the importance of using such medicines under professional medical guidance.
The FDA decision could also influence future treatment approaches for people living with diabetes and cardiovascular disease worldwide.
